BCAX Bicara Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2023658 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-81.3%
TTM EPS YoY-164.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-54.2%
ROA-49.8%
ROIC (approx.)-67.1%
Asset turnover—
Leverage & solvency
Liabilities / assets11.1%
Debt / equity0.00x
Current ratio8.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | — | $63.60M | $30.60M |
| SG&A expense | $30.51M | $18.77M | $9.27M |
| Operating income | -$155.60M | -$82.39M | -$39.89M |
| Pretax income | -$137.73M | -$67.81M | -$51.98M |
| Income tax | $217,000 | $187,000 | $5,000 |
| Net income | -$137.95M | -$68.00M | -$51.98M |
| EBITDA | -$155.50M | -$82.33M | -$39.87M |
| EPS (basic) | -2.52 | -4.05 | -89.61 |
| EPS (diluted) | -2.52 | -4.05 | -89.61 |
| Weighted avg. shares (diluted) | 54.68B | 16.81B | 580.11M |
| Balance sheet | |||
| Cash & equivalents | $96.69M | $489.71M | $230.44M |
| Short-term investments | $318.12M | $0 | — |
| Current assets | $422.05M | $502.53M | $231.07M |
| PP&E, net | $330,000 | $155,000 | $202,000 |
| Total assets | $430.99M | $510.00M | $233.98M |
| Current liabilities | $28.95M | $17.99M | $15.09M |
| Total liabilities | $29.54M | $18.12M | $15.47M |
| Shareholders' equity | $401.45M | $491.88M | -$148.77M |
| Shares outstanding | 56.60M | 54.44M | 640,386 |
| Cash flow statement | |||
| Operating cash flow | -$106.83M | -$74.75M | -$45.63M |
| Capital expenditure | $280,000 | $71,000 | $586,000 |
| Free cash flow | -$107.11M | -$74.82M | -$46.21M |
| Investing cash flow | -$318.45M | -$9,000 | -$586,000 |
| Financing cash flow | $32.26M | $334.03M | $272.50M |
| Depreciation & amortization | $105,000 | $56,000 | $19,000 |
| Stock-based compensation | $15.01M | $7.40M | $1.90M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.